Solid Biosciences (SLDB) Equity Average (2018 - 2024)
Solid Biosciences (SLDB) has disclosed Equity Average for 7 consecutive years, with $180.1 million as the latest value for Q3 2024.
- Quarterly Equity Average rose 16.94% to $180.1 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $180.1 million through Sep 2024, up 16.94% year-over-year, with the annual reading at $169.1 million for FY2023, 19.47% down from the prior year.
- Equity Average hit $180.1 million in Q3 2024 for Solid Biosciences, down from $202.0 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $245.5 million in Q2 2021 to a low of $31.5 million in Q3 2020.
- Historically, Equity Average has averaged $159.1 million across 5 years, with a median of $173.9 million in 2022.
- Biggest five-year swings in Equity Average: crashed 65.98% in 2020 and later surged 632.88% in 2021.
- Year by year, Equity Average stood at $77.2 million in 2020, then soared by 179.67% to $215.8 million in 2021, then fell by 17.76% to $177.5 million in 2022, then dropped by 23.69% to $135.4 million in 2023, then soared by 33.02% to $180.1 million in 2024.
- Business Quant data shows Equity Average for SLDB at $180.1 million in Q3 2024, $202.0 million in Q2 2024, and $168.6 million in Q1 2024.